What is Complete Genomics?
Based in San Jose, California, Complete Genomics has operated as a center of excellence for genomic research and development since its founding in 2005. The company specializes in human genome sequencing, providing high-quality, comprehensive data to researchers and clinicians. By developing a proprietary sequencing platform, the firm has positioned itself at the forefront of the digital biology revolution, enabling large-scale genetic analysis that was previously cost-prohibitive. Its market position is defined by its commitment to precision, scalability, and the democratization of genomic information, which serves as a foundational element for modern personalized medicine and diagnostic innovation.
How much funding has Complete Genomics raised?
Complete Genomics has raised a total of $197M across 7 funding rounds:
Series A
$6M
Series B
$12M
Series C
$26.5M
Debt
$14.5M
Series D
$45M
Series E
$39M
Stock Offering
$54M
Series A (2006): $6M with participation from Enterprise Partners Venture Capital and OVP Venture Partners
Series B (2007): $12M, investors not publicly disclosed
Series C (2008): $26.5M supported by Enterprise Partners VI L.P., Prospect Venture Partners III L.P., OVP Venture Partners VI L.P., and Highland Crusader Offshore Partners L.P.
Debt (2009): $14.5M, investors not publicly disclosed
Series D (2009): $45M backed by OrbiMed, Prospect Venture Partners, Essex Woodlands Health Ventures, OVP Venture Partners, and Highland Capital Partners
Series E (2010): $39M with participation from Sands Capital, Highland Capital Partners, OVP Venture Partners, OrbiMed, Prospect Venture Partners, and Essex Woodlands Health Ventures
Stock Issuance/Offering (2010): $54M, investors not publicly disclosed
Key Investors in Complete Genomics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation cycles.
Prospect Venture Partners
A prominent life sciences venture capital firm that supports innovative biomedical companies from seed to growth stage, with a focus on fostering industry-wide innovation.
Essex Woodlands Health Ventures
A healthcare growth equity firm that partners with management teams in the pharmaceuticals and MedTech sectors to provide strategic guidance and accelerate business expansion.
What's next for Complete Genomics?
Looking ahead, the strategic deployment of the $54M will likely focus on accelerating the commercial adoption of its sequencing services and enhancing its data interpretation capabilities. As the genomics industry shifts toward clinical integration, Complete Genomics is well-positioned to leverage its established infrastructure to capture additional market share. The firm's ability to maintain strong relationships with specialized healthcare investors suggests a long-term focus on sustainable growth and technological leadership. Future milestones will likely involve expanding its diagnostic partnerships and optimizing its operational efficiency to maintain a competitive edge in the rapidly evolving biotechnology landscape.
See full Complete Genomics company page
